Related references
Note: Only part of the references are listed.Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?
Dorota Zarebska-Michaluk et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort
Yu Jun Wong et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial
Robert S. Brown et al.
JOURNAL OF HEPATOLOGY (2020)
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
HEPATOLOGY (2020)
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis
Pietro Lampertico et al.
JOURNAL OF HEPATOLOGY (2020)
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort
Alessandro Soria et al.
LIVER INTERNATIONAL (2020)
Real-world Effectiveness of Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C in British Columbia, Canada: A Population-Based Cohort Study
James Wilton et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naive, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Steven L. Flamm et al.
ADVANCES IN THERAPY (2020)
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Compensated Cirrhosis
Pietro Lampertico et al.
ADVANCES IN THERAPY (2020)
EASL recommendations on treatment of hepatitis C: Final update of the series
Jean-Michel Pawlotsky et al.
JOURNAL OF HEPATOLOGY (2020)
Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection
Robert Flisiak et al.
POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ (2020)
Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3
Pamela S. Belperio et al.
JOURNAL OF HEPATOLOGY (2019)
Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review
Arnolfo Petruzziello et al.
JOURNAL OF CLINICAL LABORATORY ANALYSIS (2019)
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection
David Wyles et al.
JOURNAL OF HEPATOLOGY (2019)
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6
Eric Lawitz et al.
JOURNAL OF VIRAL HEPATITIS (2019)
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study
Marcello Persico et al.
LIVER INTERNATIONAL (2019)
Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver
W. M. H. d'Avigdor et al.
SCIENTIFIC REPORTS (2019)
Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort
Lucia Macken et al.
JOURNAL OF MEDICAL VIROLOGY (2019)
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
Roberta D'Ambrosio et al.
JOURNAL OF HEPATOLOGY (2019)
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis
Steven Flamm et al.
JOURNAL OF VIRAL HEPATITIS (2019)
Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in Korea
Sang Soo Lee et al.
JOURNAL OF VIRAL HEPATITIS (2019)
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry
Thomas Berg et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C )
Fred Poordad et al.
ANTIVIRAL THERAPY (2019)
Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03)
Malte H. Wehmeyer et al.
JOURNAL OF MEDICAL VIROLOGY (2018)
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III)
S. D. Shafran et al.
JOURNAL OF VIRAL HEPATITIS (2018)
High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection
J. von Felden et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis
Rafael Esteban et al.
GASTROENTEROLOGY (2018)
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial
Graham R. Foster et al.
HEPATOLOGY (2018)
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial
David Wyles et al.
HEPATOLOGY (2018)
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis
Massimo Puoti et al.
JOURNAL OF HEPATOLOGY (2018)
Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?
Dorota Zarebska-Michaluk et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2018)
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
S. Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Analysis of hepatitis C virus type and subtype distribution in Hungary
Gervain Judit
ORVOSI HETILAP (2018)
Epidemic history of hepatitis C virus genotypes and subtypes in Portugal
Claudia Palladino et al.
SCIENTIFIC REPORTS (2018)
Short-Duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir for Hepatitis C: A Randomized Trial
Eric Lawitz et al.
HEPATOLOGY (2017)
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Ira M. Jacobson et al.
GASTROENTEROLOGY (2017)
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis
Paul Y. Kwo et al.
JOURNAL OF HEPATOLOGY (2017)
EASL Recommendations on Treatment of Hepatitis C 2016
JOURNAL OF HEPATOLOGY (2017)
Efficacy of 12 or 18weeks of elbasvir plus grazoprevir with ribavirin in treatment-naive, noncirrhotic HCV genotype 3-infected patients
E. Gane et al.
JOURNAL OF VIRAL HEPATITIS (2017)
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme
Christophe Hezode et al.
LIVER INTERNATIONAL (2017)
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
M. Bourliere et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study
Olav Dalgard et al.
PLOS ONE (2017)
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials
Eric Lawitz et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection
M. Cornberg et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study
Jordan J. Feld et al.
CLINICAL INFECTIOUS DISEASES (2016)
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naive or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections
Edward J. Gane et al.
GASTROENTEROLOGY (2016)
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial
Edward J. Gane et al.
GASTROENTEROLOGY (2016)
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System
George N. Ioannou et al.
GASTROENTEROLOGY (2016)
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)
Vincent Leroy et al.
HEPATOLOGY (2016)
APASL consensus statements and recommendation on treatment of hepatitis C
Masao Omata et al.
HEPATOLOGY INTERNATIONAL (2016)
Literature review of the distribution of hepatitis C virus genotypes across Europe
Alfredo Alberti et al.
JOURNAL OF MEDICAL VIROLOGY (2016)
Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes
Arnolfo Petruzziello et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Predictors of sustained virological response in patients with hepatitis C virus genotype 3 infection
Dorota Zarebska-Michaluk et al.
CLINICAL AND EXPERIMENTAL HEPATOLOGY (2016)
Prevalence of HCV genotypes in Poland - the EpiTer study
Robert Flisiak et al.
CLINICAL AND EXPERIMENTAL HEPATOLOGY (2016)
Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection
Graham R. Foster et al.
GASTROENTEROLOGY (2015)
Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection
Edward J. Gane et al.
GASTROENTEROLOGY (2015)
Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection
Gregory J. Dore et al.
GASTROENTEROLOGY (2015)
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection
Jean-Michel Pawlotsky et al.
HEPATOLOGY (2015)
Sofosbuvir With Peginterferon-Ribavirin for 12 Weeks in Previously Treated Patients With Hepatitis C Genotype 2 or 3 and Cirrhosis
Eric Lawitz et al.
HEPATOLOGY (2015)
All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study
David R. Nelson et al.
HEPATOLOGY (2015)
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
Raymond T. Chung et al.
HEPATOLOGY (2015)
EASL Recommendations on Treatment of Hepatitis C 2015
JOURNAL OF HEPATOLOGY (2015)
Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection
Eric Lawitz et al.
JOURNAL OF INFECTION (2015)
Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis A Multicenter Cohort Study
Ewa Janczewska et al.
MEDICINE (2015)
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
G. R. Foster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Global Distribution and Prevalence of Hepatitis C Virus Genotypes
Jane P. Messina et al.
HEPATOLOGY (2015)
HCV Genotype 3 Is Associated With an Increased Risk of Cirrhosis and Hepatocellular Cancer in a National Sample of US Veterans With HCV
Fasiha Kanwal et al.
HEPATOLOGY (2014)
Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: Final results from the STEPS trial
D. Shoeb et al.
JOURNAL OF HEPATOLOGY (2014)
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Risk of Long-term Morbidity and Mortality in Patients With Chronic Hepatitis C Results From an Analysis of Data From a Department of Veterans Affairs Clinical Registry
Jeffrey McCombs et al.
JAMA INTERNAL MEDICINE (2014)
Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202)
Oliver Lenz et al.
JOURNAL OF HEPATOLOGY (2013)
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
JOURNAL OF HEPATOLOGY (2013)
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
Eric Lawitz et al.
LANCET INFECTIOUS DISEASES (2013)
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Edward J. Gane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections
Graham R. Foster et al.
GASTROENTEROLOGY (2011)
HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis
G. Nkontchou et al.
JOURNAL OF VIRAL HEPATITIS (2011)
Role of Hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and meta-analysis
A. Probst et al.
JOURNAL OF VIRAL HEPATITIS (2011)
Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial
Fabrizio Mecenate et al.
BMC GASTROENTEROLOGY (2010)
Adverse Outcomes in Alaska Natives Who Recovered From or Have Chronic Hepatitis C Infection
Brian J. McMahon et al.
GASTROENTEROLOGY (2010)
Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway
Candice Jackel-Cram et al.
JOURNAL OF GENERAL VIROLOGY (2010)
Hepatitis C Virus Genotype 3 and the Risk of Severe Liver Disease in a Large Population of Drug Users in France
Christine Larsen et al.
JOURNAL OF MEDICAL VIROLOGY (2010)
Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: A meta-analysis
Sara Raimondi et al.
JOURNAL OF HEPATOLOGY (2009)
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C
Pierre-Yves Bochud et al.
JOURNAL OF HEPATOLOGY (2009)
Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis
A. Andriulli et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
Olav Dalgard et al.
HEPATOLOGY (2008)
Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3
J. Powis et al.
JOURNAL OF VIRAL HEPATITIS (2008)
Hepatitis c virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: A seventeen-year prospective cohort study
Savino Bruno et al.
HEPATOLOGY (2007)
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial
Ira M. Jacobson et al.
HEPATOLOGY (2007)
Hepatitis C and steatosis
Einar Bjornsson et al.
ARCHIVES OF MEDICAL RESEARCH (2007)
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
Mitchell L. Shiffman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Mechanisms and significance of liver steatosis in hepatitis C virus infection
Francesco Negro
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis
Silvia Mirandola et al.
GASTROENTEROLOGY (2006)
Peroxisome proliferator-activated receptor-alpha and -gamma rnRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection
A De Gottardi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Steatosis in chronic hepatitis C: Why does it really matter?
T Asselah et al.
GUT (2006)
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C
L Fartoux et al.
GUT (2005)
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3
A Mangia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation
K Abid et al.
JOURNAL OF HEPATOLOGY (2005)
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose
SJ Hadziyannis et al.
ANNALS OF INTERNAL MEDICINE (2004)
Steatosis affects chronic hepatitis C progression in a genotype specific way
L Rubbia-Brandt et al.
GUT (2004)
Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C:: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis
L Castéra et al.
GUT (2004)
Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease
A Lonardo et al.
GASTROENTEROLOGY (2004)
Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response
D Kumar et al.
HEPATOLOGY (2002)
Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity
LE Adinolfi et al.
HEPATOLOGY (2001)
Share Paper
